IBCN 2019: Association of Immunohistochemical Markers Molecular Subtypes in Bladder Cancer

Aarhus, Denmark (UroToday.com) Dr. Charles Guo from the University of Texas MD Anderson Cancer Center presented data investigating immunohistochemical markers that may be associated with molecular subtypes in bladder cancer. Fresh frozen samples (n=132) and formalin-fixed paraffin-embedded (FFPE) samples (n=89) from patients with bladder cancer, with genomic mRNA expression characterized.  Gene signatures for luminal and […]

IBCN 2019: Genomic Classifier to Predict Luminal Bladder Tumors

Aarhus, Denmark (UroToday.com) Joep J. de Jong from the Erasmus MC Cancer Institute in Rotterdam discussed efforts at developing a genomic classifier to predict clinically aggressive luminal bladder tumors.  Using TURBT specimens from 206 patients with high-grade cT1-T2 N0M0 bladder cancer who subsequently underwent radical cystectomy without neoadjuvant chemotherapy, patients who were found to be […]

Magnetic Resonance Imaging to Differentiate the Histology of Testicular Masses: A Systematic Review of Studies with Pathologic Confirmation.

Ultrasound is the imaging modality of choice to evaluate scrotal pathology. However, differentiating malignant and benign testicular tumors is not always possible, and there is interest in evaluating magnetic resonance imaging (MRI) as a potential adjunct for diagnosis. We conducted a systematic review and found nine studies related to MRI diagnosis of testicular masses. A […]

Upper urinary tract urothelial carcinoma on multidetector CT: spectrum of disease.

Urothelial carcinoma of the upper urinary tract (UUT) is a relatively uncommon genitourinary malignancy, accounting for about 5-7% of urothelial tumors. The significant features of this tumor are multifocality and high rate of recurrence. Computed tomography urography (CTU) has replaced excretory urography (EU) and retrograde pyelography (RP) for imaging of upper tract urothelial carcinoma. While […]

Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinic

Given the relative novelty of stereotactic body radiation therapy as a treatment modality low-risk and intermediate-risk prostate cancer, little data exist evaluating dosimetry and its impact on patient-reported quality of life (PR-QOL) metrics. Herein, we present an interim analysis of a phase II clinical trial of PR-QOL and dosimetric correlates. Patients with biopsy-proven low-risk or […]

Prostate radiotherapy in newly diagnosed metastatic prostate cancer.

The aim of this article is to review the role of prostate radiotherapy in the multimodal management of newly diagnosed metastatic hormone naïve prostate cancer. Two randomized controlled trials have evaluated the role of prostate radiotherapy with systemic therapy (androgen deprivation therapy ± docetaxel) in newly diagnosed metastatic hormone-naive prostate cancer. In a combined cohort of over […]

Renal Cell Carcinoma Follow-Up – Is it Time to Abandon Ultrasound?

We wished to compare the efficacy of ultrasound versus intravenous contrast-enhanced computed tomography (CT) for detecting recurrent renal cell carcinoma (RCC) by identifying patients presenting with such tumor burden and to evaluate the utility of these imaging modalities in these circumstances. Patients who developed local and/or distant recurrences following surgical intervention for RCC were identified. […]

Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition.

Acquiring multiparametric magnetic resonance images of the prostate is not a simple “push-button” approach. To show how image acquisition of prostate multiparametric Magnetic Resonance Imaging (mpMRI) can be optimized. Image protocols, magnetic field strength choice, and the use of receiver coils are discussed. In addition, patient preparation and the recognition, prevention, and mitigation of artifacts […]

Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.

The 2019 European Association of Urology guidelines recommend multiparametric magnetic resonance imaging (mpMRI) for biopsy-naïve patients with clinical suspicion of prostate cancer (PC) and avoiding biopsy in patients with negative mpMRI and low clinical suspicion. However, consensus on the optimal definition of low clinical suspicion is lacking. We evaluated 266 biopsy-naïve patients who underwent mpMRI, […]

Active treatment in low-risk prostate cancer: a population-based study.

Active surveillance instead of active treatment (at) is preferred for patients with low-risk prostate cancer (lr-pca), but practice varies widely. We conducted a population-based study to assess the proportion of patients who underwent at between January 2011 and December 2014, and to evaluate factors associated with at. The provincial cancer registry was linked to administrative […]

X